Seeking Alpha

Amarin (AMRN +1%) gains after saying it's submitted a Supplemental New Drug Application with the...

Amarin (AMRN +1%) gains after saying it's submitted a Supplemental New Drug Application with the FDA seeking approval for the marketing and sale of Vascepa capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides with mixed dyslipidemia. The drug is already approved to treat hypertriglyceridemia, and if cleared for the new indication, it will be the only approved prescription omega 3 therapy for cardiovascular health management in this patient population.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector